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D
9 -Tetrahydrocannabinol (D 9 -THC) is a psychoactive ingredient of marijuana and is known to exhibit a variety of pharmacological activities in vitro and in vivo. 1) For example, D 9 -THC induces euphoria, heightened sensory awareness, altered cognition, inhibition of memory and reduced spontaneous activity. Noticeably, D 9 -THC also exerts several beneficial effects such as analgesia, antiemesis, promotion of appetite and immunosuppression in humans and in experimental animals; cannabimimetic molecules without deleterious activities should be of potential value as possible therapeutic drugs.
The mechanism underlying various in vitro and in vivo actions of cannabinoids remained unclear until the late 1980's. It has long been assumed that the effects of D 9 -THC may be due to the membrane perturbation of target tissues and cells. Studies by several investigators in this decade, however, revealed that various cannabinoids including D 9 -THC interact with specific receptor sites, 2) termed the CB1 receptor (present primarily in the nervous system) 3) and the CB2 receptor (present mainly in the immune system), 4) thereby eliciting the responses.
The discovery of such specific receptor sites for the cannabinoids prompted a search for the endogenous ligand as in the case of opioids. To date, two types of arachidonic acid-containing molecules have been proposed as putative endogenous ligands: N-arachidonoylethanolamine (anandamide) 5 ) and 2-arachidonoylglycerol (1). [6] [7] [8] Recently, we provided evidence that 1 but not anandamide is the endogenous natural ligand for the cannabinoid CB1 receptor. 9, 10) Compound 1 is a potent full agonist toward the CB1 receptor and exhibits various cannabimimetic activities such as the inhibition of adenylyl cyclase in mouse splenocytes, inhibition of twitch response in mouse vas deferens, modulation of proliferation of mouse lymphocytes, Ca 2ϩ transients in NG108-15 cells, inhibition of long-term potentiation in hippocampus and the induction of hypomotility, hypothermia and analgesia when administered to mice. [7] [8] [9] [10] [11] [12] [13] Compound 1 is the natural ligand of the cannabinoid receptor; it seems possible that cannabimimetic compounds without undesirable deleterious properties and therapeutically valuable will be found from among the structural analogues or derivatives of 1. One important problem concerning 1 as a pharmacological tool or a therapeutic drug is that it is very easily cleaved by hydrolyzing enzymes. 14, 15) The development of metabolically stable analogues is, therefore, essential. Previously, we 10) and Mechoulam et al. 16) developed an ether-linked analogue of 2-arachidonoylglycerol (2). This compound exhibited appreciable agonistic activities in vitro and in vivo. 10, 16) However, detailed information including the chemical data concerning the synthesis of this novel class of the 2-arachidonoylglycerol analogue has not yet been reported. Furthermore, not much is yet known concerning the chemical synthesis of 1 itself. It is important to provide detailed information concerning chemical synthesis of these compounds in order to develop more potent and valuable analogues of 2-arachidonoylglycerol in the future. It is also necessary to develop an analogue of 2 lacking agonistic activity as a control molecule, because high concentrations of the ether-linked analogues of the monoacylglycerols may also exert nonspecific physiocochemical effects such as detergent effects.
Here, we report the biological activities as well as details of the chemical synthesis of 1, its ether-linked analogue (2) which acts as the CB1 receptor agonist, and the newly developed ether-linked analogues of 2-arachidonoylglycerol (3)-(5) which lack agonistic activities toward the CB1 receptor.
Results and Discussion
As shown in Chart 1, the synthesis of 2-arachidonoylglycerol (1) was carried out from commercially available arachi-donic acid and glycerol. The primary hydroxy groups of glycerol were selectively protected by benzaldehyde using 5-sulfosalicilic acid dihydrate as a catalyst in benzene, and then recrystallized from benzene/hexane to give a secondary alcohol 6 in 17% yield. Esterification of the arachidonic acid with alcohol 6 using 4-dimethylaminopyridine (DMAP) and N,N-dicyclohexylcarbodiimide (DCC) in dry toluene at room temperature for 6 h provided ester 7 in 79% yield. Deprotection of the benzylidene group was accomplished by dissolving ester 7 in trimethyl borate at room temperature followed by the addition of boric acid.
17) The reaction mixture was stirred at 100°C for 30 min, then cooled to room temperature. Chromatography on silica gel gave 1 in 69% yield with 55% conversion. In this process, about 10% of transesterification was observed in 1 by 1 H-NMR, therefore, compound 1 was further purified by borate-impregnated TLC to remove any contaminating 1-or 3-isomer. The purity was confirmed by 13 C-NMR and MS. Recently, Han and Razdan 18) also reported the chemical synthesis of 2-arachidonoylglycerol, although their method employing triisopropylsilyl chloride as a hydroxy group-protecting reagent was different from our currently described procedure. The advantage in using 1,3-benzylideneglycerol (6) for the synthesis of 1 and its analogues is that the coupling products 7, 10, 13, and 15 are detectable under UV lamp (254 nm).
Chart 2 summarizes the synthesis of an ether-linked analog of 2-arachidonoylglycerol, 2-(5,8,11,14-eicosatetraenyl)-glycerol (2), which is a metabolically stable cannabinoid receptor ligand. To make an ether bond, arachidonic acid was first converted to an alcohol 8 with lithium aluminum hydride (LiAlH 4 ) in dry diethyl ether at 0°C, and then treated with methyltriphenoxyphosphonium iodide in N,N-dimethylformamide (DMF) to give the iodo derivative 9 in good yield. 2-(5,8,11,14-Eicosatetraenyl)-1,3-benzylideneglycerol (10) was obtained by condensing 9 and 6 using Ag 2 O and tetra-n-butylammonium iodide (n-Bu 4 NI) in DMF. After stirring at 90°C for 6 h in the dark, the coupling product 10 was isolated in 30% yield. Finally, deprotection of the benzylidene group in 10 with boric acid and trimethyl borate gave 2 in 62% yield.
The synthesis of an ether-linked analogue of monoarachidonoylethyleneglycol (1-eicosatetraenyloxyethanol (3)) is outlined in Chart 3. The coupling of 5,8,11,14-eicosatetraenyl iodide (9) with 3-(tert-butyldimethylsilyl)oxyethanol and subsequent removal of the tert-butyldimethylsilyl (TBDMS) ether moiety in 11 by treatment with tetrabutylammonium fluoride (TBAF) gave 3 in 22% yield in two steps.
2-Hexadecylglycerol (4) was prepared from commercially available hexadecanol as shown in Chart 4. The alcohol was converted to the iodide 12 using methyltriphenoxyphosphonium iodide in DMF. The coupling of 12 with 1,3-benzylideneglycerol gave 13, which was then hydrolyzed to give 4 as described for 2.
2-(9-Octadecenyl)glycerol (5) was synthesized from commercially available cis-9-octadecen-1-ol as shown in Chart 5. The iodide 14 was obtained in 80% yield using methyltriphenoxyphosphonium iodide in DMF. The coupling of 14 with 1,3-benzylideneglycerol gave 15, which was then hydrolyzed to give 5 as described for 2. Figure 1 shows the effects of 1, 2 and related compounds 3-5 on the intracellular free Ca 2ϩ concentrations ([Ca 2ϩ ] i ) in NG108-15 cells which are known to express the cannabi-noid CB1 receptor. Low concentrations of 1 induce rapid transient increases in [Ca 2ϩ ] i in the NG108-15 cells; the response was detectable from as low as 1 nM, reaching a maximum around 10 mM. Such a response induced by 1 was blocked by pretreatment of the cells with SR141716A, a cannabinoid CB1 receptor-specific antagonist (data not shown), suggesting that rapid transient increases in [Ca 2ϩ ] i occurred through a CB1 receptor-dependent mechanism. Noticeably, 2 also exhibited appreciable agonistic activity, yet its activity was significantly lower than that of 1. These observations are in general agreement with the result reported earlier, 10) but appear to be inconsistent with the result of the in vivo experiment where 2 exhibited much more potent biological activity than 1. 16) We also found that an ether-linked analogue of monoarachidonoylethyleneglycol (3) possesses some weak agonistic activity.
We next examined the activities of the structural analogues of 2 having saturated or monoenoic fatty chains. We found that neither the ether-linked analogue of 2-palmitoylglycerol (4) nor the ether-linked analogue of 2-oleoylglycerol (5) elicits rapid, transient increases in [Ca 2ϩ ] i . It is apparent, therefore, that both 4 and 5 are devoid of appreciable agonistic activity toward the cannabinoid CB1 receptor. Compound 2 is resistant to hydrolyzing enzymes and may exist for a long period in vitro or in vivo without receiving hydrolysis; thus, in some cases, it is not clear whether the effects of 2 are mediated only through the cannabinoid receptors or also through other sites of action. To clarify this issue, compounds 4 and 5, which lack cannabimimetic activity, should be valuable tools.
Despite the increasing attention paid to 1 these days, 19, 20) information concerning it and its structural analogues is still quite limited. Thus, the synthesis of a number of 2-arachidonoylglycerol analogues and evaluation of their biological and pharmacological activities are essential to better understand the physiological significance of 1 and to develop a new class of therapeutic drugs that acts on the cannabinoid receptors in the future.
Experimental
General Methods Melting points were determined using a Yanagimoto hot-stage melting point apparatus and are uncorrected.
1 H-NMR and 13 C-NMR spectra were recorded in CDCl 3 on a GSX 400 spectrometer. Chemical shifts are given in ppm (d) using tetramethylsilane (TMS) as the internal standard. Mass spectra were registered on a JMS SX-102A instrument. Elemental analysis was performed with a Perkin-Elmer 2400 II instrument. Column chromatography was carried out on silica gel 60 (70-230 mesh, Merck) and preparative TLC was run on silica gel 60 F 254 (Merck). Unless otherwise noted, all reagents were purchased from commercial suppliers and used as received.
1,3-Benzylideneglycerol (6) Glycerol (120 g, 1.30 mol), benzaldehyde (120 g, 1.13 mol), and 5-sulfosalicylic acid dihydrate (1.20 g, 55.0 mmol) were dissolved in benzene (120 ml), and the mixture was then refluxed at 120°C overnight with a Dean-Stark apparatus to remove the water. After having cooled to room temperature, the reaction mixture was diluted with diethyl ether (500 ml) and washed with saturated aqueous NaHCO 3 and brine. The organic layer was dried over MgSO 4 followed by filtration and evaporation. The residue was recrystallized from benzene/hexane (20 : 1) (2 l) to give 6 (41 g, yield 17%) as white needles: mp 79-81°C. 2-Arachidonoyl-1,3-benzylideneglycerol (7) To a solution of 6 (60 mg, 330 mmol) and arachidonic acid (all-cis-5,8,11,14-eicosatetraenoic acid) (100 mg, 328 mmol) in dry toluene (30 ml) was added DCC (136 mg, 656 mmol) and DMAP (12 mg, 99 mmol). The reaction mixture was stirred at room temperature for 6 h, then diluted with ethyl acetate (EtOAc) (50 ml). The mixture was washed with water (50 ml) and brine (50 ml), and the organic layer was dried over MgSO 4 2-Arachidonoylglycerol (1) A suspension of 7 (500 mg, 1.07 mmol) and boric acid (132 mg, 2.13 mmol) in trimethyl borate (5 ml) was refluxed at 100°C for 20 min. After having cooled to room temperature, the reaction mixture was diluted with EtOAc (100 ml) and successively washed with 50 ml of water and brine. The organic layer was dried (MgSO 4 ), and the solvent was removed. Silica gel column chromatography (hexane/EtOAc, the ratio ranging from 1 : 1 to 0 : 1, v/v) of the crude residue provided the product 1 (280 mg, 69%) as a colorless oil. Further, compound 1 (12.0 mg) was purified by borate-impregnated TLC to remove contaminating 1-or 3-isomer. Then, pure 1 (10.7 mg) was obtained in 89% yield as a colorless oil: 1 2-(5,8,11,14-Eicosatetraenyl)-1,3-benzylideneglycerol (10) 1,3-Benzylideneglycerol (6) (200 mg, 1.11 mmol), Ag 2 O (191 mg, 824 mmol) and nBu 4 NI (20 mg, 55 mmol) were added to a stirred solution of iodide 9 (220 mg, 550 mmol) in DMF (10 ml) at room temperature under argon. The suspension was stirred at 90°C for 6 h in the dark. After having cooled to room temperature, the mixture was diluted with EtOAc (100 ml) and water (100 ml). The generated silver was removed by filtering through Celite, and the filtrate was successively washed with 100 ml of water and brine. The organic layer was dried over MgSO 4 and evaporated to dryness. Column chromatography on silica gel (hexane/EtOAc, 5 : 1, v/v) of the crude residue gave 10 (109 mg, 44%) as a colorless oil: 43 mmol) at room temperature. The suspension was stirred at 90°C for 6 h under argon in the dark. After having cooled to room temperature, the reaction mixture was diluted with EtOAc (30 ml) and water (20 ml) followed by filtration through Celite to remove the generated silver. The filtrate was successively washed with 100 ml of water and brine. The organic layer was dried over MgSO 4 then removed in vacuo. The crude residue 11 was used in the next step without further purification. Namely, a 1.0 M solution of TBAF in THF (870 mmol/870 ml) was added dropwise to crude silyl ether 11 in THF (5 ml) at 0°C under argon. The reaction mixture was warmed to room temperature and stirred for 1 h. Removal of the solvent and subsequent chromatography on silica gel (hexane/EtOAc, 5 : 1 to 3 : 1, v/v) of the residue gave pure 3 (33 mg, 22% in two steps) as a colorless oil: ] i in neuroblastomaϫ glioma hybrid NG108-15 cells was determined using Fura-2/AM in a CAF-100 Ca 2ϩ analyzer as previously described. [9] [10] [11] 
